Abstract The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have developed ROCK (rock.icr.ac.uk) to provide a unique, publicly accessible resource for the integration of breast cancer functional and molecular profiling datasets. ROCK provides a simple online interface for the navigation and cross-correlation of gene expression, aCGH and RNAi screen data. It enables the interrogation of gene lists in the context of statistically analysed functional genomic datasets, interaction networks, pathways, GO terms, mutations and drug targets. The interface also provides interactive visualisations of datasets and interaction networks. ROCK collates data from a wealth of breast cancer molecular profiling and functional screening studies into a single portal, where analysed and annotated results can be accessed at the level of a gene, sample or study. We believe that portals such as ROCK will not only afford researchers rapid access to profiling data, but also aid the integration of different data types, thus enhancing the discovery of novel targets and biomarkers for breast cancer.
Introduction
Breast cancer rates have increased by more than 50% over the last 20 years and breast cancer is now the most common cancer in the UK, with more than 46,000 women diagnosed each year, and more than a million cases worldwide [1] . Breast cancer is a heterogeneous disease, comprising multiple entities with distinct risk factors, biological features, histopathological characteristics and response to therapies. In the last decade, a wide range of molecular profiling approaches have been employed in an attempt to identify sub-types of breast cancer [2] [3] [4] [5] with the aim of better understanding the disease process and identifying novel therapeutic approaches. More recently, functional genomic methods such as RNA interference (RNAi) screens have aimed to identify new molecular targets, such as genes that are recurrently amplified, overexpressed and functionally required for viability in a range of cancer cell lines [6] . Indeed, use of these and other functional genomic approaches is set to grow as they offer the potential to identify novel therapeutic targets in breast cancer sub-types that are unresponsive to existing treatment regimes.
Gene-specific data from large-scale profiling studies are often difficult to access from supplementary material in manuscripts or microarray data repositories [7, 8] . This is largely due to different data formats, gene identifiers and sample annotations being used in different studies. Furthermore, many functional genomic studies generate largescale datasets that can be mined in a number of different ways from those originally published. In order to address these issues, we have developed ROCK (rock.icr.ac.uk) to provide a unique, publicly accessible resource for the analysis and integration of breast cancer functional genomic datasets.
ROCK provides an intuitive online interface for the navigation, cross-linking and cross-correlation of microarray gene expression, DNA copy number (array competitive genomic hybridisation) and RNAi screen data from breast cancer cell lines and tumour samples. The interface was designed to provide researchers with access to the results of statistical analysis of key molecular and functional profiling datasets at the level of a single gene, gene list, sample or study. Thus, ROCK enables breast cancer researchers to quickly assess the potential significance of genes of interest in the context of prior knowledge in the field.
Furthermore, we believe that integration of molecular and functional profiling datasets in resources such as ROCK can aid classification of breast cancer sub-types leading to improved prediction of prognosis and response to treatment.
The database
The ROCK resource is based on a number of key breast cancer functional genomics and somatic mutation datasets collated from literature and online resources [7] [8] [9] [10] . Public gene expression, aCGH and RNAi datasets have been systematically analysed using well-established methodologies to enable users to mine the most useful data quickly and easily.
In order to facilitate the analysis and integration of breast tumour datasets, annotations in various formats were translated into a consistent ontology detailing tumour pathology [11] , tumour macroscopy [12] , histological grading [13] , tumour staging [14] and molecular markers (including oestrogen receptor (ER), progesterone receptor (PgR), androgen receptor (AR), HER2 and Ki67 staining, as well as p53, BRCA1 and BRCA2 mutation status).
In the case of microarray gene expression studies, four key analyses were performed on each dataset. Firstly, the breast cancer subtype for each sample in each study was predicted using centroid correlation to the PAM50 classifier [5, 15] . Secondly, significance analysis of microarrays (SAM) [16] was performed on each dataset using predicted breast cancer subtype as well as common classes of functional annotations such as oestrogen receptor (ER) status and tumour grade to delineate sample groups. Thirdly, groups of co-expressed genes were identified using the Pearson correlation (r [ 0.5, adjusted P value \ 0.01). Finally, survival analysis (survival package in R) was performed for each gene in each study (where survival and censoring data were available) to identity genes where expression had potential clinical predictive or prognostic value.
For aCGH datasets, normalised data from individual studies were smoothed using circular binary segmentation [17] to translate noisy intensity measurements into regions of equal copy number, then scaled to the genome median absolute deviation. Recurrent gains, losses, amplifications and deletions ([10% samples) were called from the smoothed and scaled data using consistent thresholds. For several studies where data were available the correlation between DNA copy number and gene expression level was assessed for each gene that could be matched across platforms. Firstly, the Pearson correlation between normalised gene expression level and smoothed CGH value was calculated for each gene in each study. Secondly, raw and adjusted [18] Wilcoxon P values for gain, loss, amplification and deletion were computed wherever relevant.
RNAi screen data were curated from literature. Where raw screen data were available analysis was performed using the cellHTS2 package in R [19] , and hits were called using screen-specific thresholds. Where screen hit or phenotypes annotations were provided by authors, these were also added to the database.
Interaction networks were constructed by amalgamating data from a range of different online resources [20] [21] [22] [23] [24] [25] [26] [27] , and supplemented with data curated in-house. Similarly, pathway datasets were parsed from public resources [23, [28] [29] [30] and assembled into a single dataset.
User interface
Within ROCK users can browse through lists of breast cancer specific gene expression and DNA copy number (aCGH) studies, RNAi screens, genetic mutations [9] and existing therapeutics [31] . For each curated gene expression study users can view graphical summaries of the available sample annotation and the various analyses already performed on the dataset. For each aCGH study users can view copy number aberration frequency plots (Fig. 1a) , and focus in on individual samples, gaining access to sample plots (Fig. 1b) , which can be zoomed into individual chromosome level. Users can also access details of specific recurrent amplicons and view lists of genes within then. Similarly, for RNAi screens users can focus upon lists of individual hits and their associated phenotypes. Furthermore, complete normalised datasets and associated standardised functional annotations are available for download, to enable bioinformaticians to pursue more detailed or specific analyses.
Alternatively, users can employ text-based searches to navigate within the database. For example, users can begin their search with a single gene of interest to identify the corresponding gene expression pattern, survival data, copy number aberrations or RNAi phenotype for that gene in any study. ROCK contains gene identifiers from Ensembl [32] , Entrez gene [33] , UniGene [34] , HUGO [35] , RefSeq [36] and CCDS [37] , along with protein data from UniProt [38] and microarray probe identifiers from Affymetrix, Illumina, Agilent and several other cDNA microarray platforms, to maximise the likelihood of identifying genes of interest. Users can search for genes from mouse [39] , yeast [40] , fly [27] or worm [41] as well as man. If a search is initiated using a non-human gene, lists of putative human orthologues will be returned from the three different homology datasets contained in the database: HomoloGene [36] , InParanoid [42] and Ensembl Compara [32] . Once a particular human gene has been selected, the user is directed to the ROCK entry for that gene. This page is divided into a set of tabs relating to different types of genespecific information.
By navigating down from the gene expression, aCGH, methylation or RNAi summary tab for each gene, users can access detailed information about the significance of that gene in each study (Fig. 2) . For example, in the case of RNAi data, details of the cell line and assay are supplied, along with phenotypic data. For expression data, users can navigate down from the initial summary to view evidence of differential regulation (Fig. 3a) , or lists of genes co-expressed with the gene of interest in particular studies (Fig. 3b) . Where data are available, users can view Kaplan-Meier survival curves for individuals expressing different levels of a given gene (Fig. 3c) , or assess the correlation between gene expression level and DNA copy number (Fig. 3d) .
From the primary gene page, users can also quickly access Gene Ontology [43] , InterPro [44] , homology [32, 36, 42] , somatic mutation [9] , small molecule [31] , protein interaction [20] [21] [22] [23] [24] [25] [26] [27] and pathway [23, 28, 29] information for that gene.
Batch searches
ROCK has been designed to allow users to analyse the results of high-throughput experiments in the context of other large-scale datasets. Thus, searches can be carried out using lists of genes, microarray probes, GO terms, protein motifs and small molecule inhibitors. Gene lists generated within the database can be saved and combined in a number of ways by registered users in the 'Account' section. All gene lists, whether from batch searches or ROCK analysis results, can be used in a variety of batch searches using the 'Link' function. Linking enables users to crossreference datasets. For example, lists of genes showing significantly different expression between ER? and ERbreast cancer samples (as established by SAM analysis) can be saved. Intersection of such lists from several studies can then be used to derive a single list of consistently differentially expressed genes. This gene list can be linked to pathway analysis, to identify statistically over-represented pathways, to network analysis, to visualise gene connectivity (Fig. 4) , or interrogated for gene annotation such as Fig. 1 Visualisation of DNA copy number data in ROCK. a Plot summarising the frequency of amplification and deletions across genome in 118 breast cancer sample from Chin et al. [46] . Amplifications are depicted in green and deletions in red. b Plot of the log ratio for sample B0165 for all BACs across the genome [46] . Red indicates los or deletion, green indicated gain or amplification, and the purple line indicates the CBS smooth cytoband, or known breast cancer somatic and germ line mutations.
Discussion and future prospects
ROCK was created to meet a clear need in the breast cancer research community for a public, integrated functional genomics resource. High-throughput experiments have formed a core part of cancer research for over a decade now, and of the solid malignancies, breast cancer has been the most extensively analysed with highthroughput methods. However, until now there has been no means for the bench scientist to easily and quickly access the vast amounts of data contained in these studies. Microarray data repositories such as GEO [7] and ArrayExpress [8] enable sharing of gene expression datasets in a standard format, but not all important cancer studies are included in these resources and they do not offer statistical analysis of the data. Oncomine [45] was developed to meet this shortfall, but it covers a much wider range of cancer types and as a result lacks a breast cancer relevant interpretation of the gene expression datasets ROCK contains. Furthermore, Oncomine [45] does not include aCGH or RNAi screen data. While expression array studies have helped to unravel molecular subgroups of breast cancer and to develop prognostic and predictive signatures, their role in the identification of novel therapeutic targets has so far [47] . b Heatmap of genes coexpressed with PPM1D in MacKay et al. [48] . c KaplanMeier survival curves for high and low expression of CDC2 in Sotiriou et al. [49] . d Correlation of gene expression with DNA copy number for ERBB2 in Neve et al. [50] been limited. The promise of high-throughput methods is likely to be realised only by the integration of multiple sources of data, including those from functional RNA interference studies.
ROCK was developed to complement existing breast cancer databases such as the Breast Cancer Information Core (http://research.nhgri.nih.gov/bic/) and the Breast Cancer Database (http://www.breastcancerdatabase.org/), which are focussed on curating literature on somatic and germline mutations in breast cancer, rather than highthroughput functional genomic studies.
The disease-specific focus of ROCK will continue to assure that it differs in its function, scope and content from other online resources. In the future, we plan to add not only new datasets for our existing range of supported experimental platforms, but also to extend the database infrastructure to support SNP genotyping data, DNA methylation arrays, shRNA barcode screens and next generation sequencing (NGS) data. Furthermore, we aim to expand our in-house curated pathways to give complete and up-to-date coverage of key breast cancer relevant pathways, particularly those involved in DNA repair and oestrogen signalling. 
